Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

PHASE4RecruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

June 28, 2023

Primary Completion Date

April 30, 2029

Study Completion Date

April 30, 2034

Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Interventions
DRUG

Somatostatin analog

Somatostatin analog treatment every 4 weeks

Trial Locations (19)

Unknown

RECRUITING

AZ Klina, Brasschaat

ACTIVE_NOT_RECRUITING

AZ Rivierenland, Rumst

ACTIVE_NOT_RECRUITING

Ghent University Hospital, Ghent

RECRUITING

VITAZ, Sint-Niklaas

RECRUITING

University Hospital Leuven, Leuven

ACTIVE_NOT_RECRUITING

Grand Hôpital de Charleroi, Charleroi

NOT_YET_RECRUITING

AZ Monica, Antwerp

ACTIVE_NOT_RECRUITING

GZA, Antwerp

WITHDRAWN

Ziekenhuis Netwerk Antwerpen, Antwerp

RECRUITING

Cliniques Universitaires Saint-Luc, Brussels

ACTIVE_NOT_RECRUITING

H.U.B., Brussels

RECRUITING

Antwerp University Hospital, Edegem

ACTIVE_NOT_RECRUITING

Centre Hospitalier Universitaire Sart Tilman, Liège

RECRUITING

Rijnstate, Arnhem

RECRUITING

Maastricht UMC+, Maastricht

ACTIVE_NOT_RECRUITING

Maxima Medisch Centrum, Eindhoven

ACTIVE_NOT_RECRUITING

Amsterdam UMC, Amsterdam

RECRUITING

UMC Groningen, Groningen

RECRUITING

Erasmus MC, Rotterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Erasmus Medical Center

OTHER

collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Belgium Health Care Knowledge Centre

OTHER_GOV

lead

University Hospital, Antwerp

OTHER